nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—CYP3A4—Bexarotene—hematologic cancer	0.029	0.0829	CbGbCtD
Olopatadine—CYP3A4—Lomustine—hematologic cancer	0.0269	0.0771	CbGbCtD
Olopatadine—CYP3A4—Busulfan—hematologic cancer	0.0269	0.0771	CbGbCtD
Olopatadine—CYP3A4—Thiotepa—hematologic cancer	0.024	0.0687	CbGbCtD
Olopatadine—CYP3A4—Methoxsalen—hematologic cancer	0.0187	0.0534	CbGbCtD
Olopatadine—CYP3A4—Bortezomib—hematologic cancer	0.0178	0.0508	CbGbCtD
Olopatadine—CYP3A4—Daunorubicin—hematologic cancer	0.017	0.0486	CbGbCtD
Olopatadine—CYP3A4—Cytarabine—hematologic cancer	0.015	0.0429	CbGbCtD
Olopatadine—CYP3A4—Teniposide—hematologic cancer	0.0148	0.0422	CbGbCtD
Olopatadine—CYP3A4—Ifosfamide—hematologic cancer	0.0136	0.039	CbGbCtD
Olopatadine—CYP3A4—Imatinib—hematologic cancer	0.013	0.0372	CbGbCtD
Olopatadine—CYP3A4—Ruxolitinib—hematologic cancer	0.0123	0.035	CbGbCtD
Olopatadine—CYP3A4—Nilotinib—hematologic cancer	0.0118	0.0338	CbGbCtD
Olopatadine—CYP3A4—Vinorelbine—hematologic cancer	0.0117	0.0335	CbGbCtD
Olopatadine—CYP3A4—Triamcinolone—hematologic cancer	0.0107	0.0307	CbGbCtD
Olopatadine—CYP3A4—Dasatinib—hematologic cancer	0.0105	0.0299	CbGbCtD
Olopatadine—CYP3A4—Mitoxantrone—hematologic cancer	0.0103	0.0295	CbGbCtD
Olopatadine—S100A2—hematopoietic system—hematologic cancer	0.00945	0.0979	CbGeAlD
Olopatadine—CYP3A4—Betamethasone—hematologic cancer	0.0092	0.0263	CbGbCtD
Olopatadine—CYP3A4—Prednisolone—hematologic cancer	0.00908	0.026	CbGbCtD
Olopatadine—CYP3A4—Prednisone—hematologic cancer	0.00857	0.0245	CbGbCtD
Olopatadine—CYP3A4—Irinotecan—hematologic cancer	0.00813	0.0232	CbGbCtD
Olopatadine—S100A12—hematopoietic system—hematologic cancer	0.00762	0.0789	CbGeAlD
Olopatadine—S100B—hematopoietic system—hematologic cancer	0.00752	0.0779	CbGeAlD
Olopatadine—CYP3A4—Vinblastine—hematologic cancer	0.00723	0.0207	CbGbCtD
Olopatadine—CYP3A4—Vincristine—hematologic cancer	0.0071	0.0203	CbGbCtD
Olopatadine—CYP3A4—Etoposide—hematologic cancer	0.00651	0.0186	CbGbCtD
Olopatadine—S100A13—gonad—hematologic cancer	0.00587	0.0608	CbGeAlD
Olopatadine—S100A2—lung—hematologic cancer	0.00549	0.0569	CbGeAlD
Olopatadine—CYP3A4—Dexamethasone—hematologic cancer	0.00535	0.0153	CbGbCtD
Olopatadine—S100A2—testis—hematologic cancer	0.00518	0.0536	CbGeAlD
Olopatadine—S100A12—blood—hematologic cancer	0.00505	0.0523	CbGeAlD
Olopatadine—S100B—blood—hematologic cancer	0.00498	0.0516	CbGeAlD
Olopatadine—S100A12—bone marrow—hematologic cancer	0.00488	0.0506	CbGeAlD
Olopatadine—S100A1—testis—hematologic cancer	0.00477	0.0494	CbGeAlD
Olopatadine—S100A13—lung—hematologic cancer	0.00448	0.0465	CbGeAlD
Olopatadine—CYP3A4—Doxorubicin—hematologic cancer	0.00444	0.0127	CbGbCtD
Olopatadine—S100A12—lung—hematologic cancer	0.00442	0.0458	CbGeAlD
Olopatadine—S100A13—testis—hematologic cancer	0.00423	0.0438	CbGeAlD
Olopatadine—S100A12—testis—hematologic cancer	0.00417	0.0432	CbGeAlD
Olopatadine—S100A1—lymph node—hematologic cancer	0.00346	0.0358	CbGeAlD
Olopatadine—S100A13—lymph node—hematologic cancer	0.00307	0.0318	CbGeAlD
Olopatadine—S100A12—lymph node—hematologic cancer	0.00303	0.0313	CbGeAlD
Olopatadine—S100B—lymph node—hematologic cancer	0.00299	0.0309	CbGeAlD
Olopatadine—S100A2—Ponatinib—Nilotinib—hematologic cancer	0.00198	0.208	CbGdCrCtD
Olopatadine—S100A13—Cyclophosphamide—Mechlorethamine—hematologic cancer	0.00156	0.164	CbGdCrCtD
Olopatadine—HRH1—hematopoietic system—hematologic cancer	0.00154	0.016	CbGeAlD
Olopatadine—S100A2—Ponatinib—Imatinib—hematologic cancer	0.0015	0.158	CbGdCrCtD
Olopatadine—S100A13—Cyclophosphamide—Ifosfamide—hematologic cancer	0.00133	0.139	CbGdCrCtD
Olopatadine—CYP3A4—hematopoietic system—hematologic cancer	0.00119	0.0123	CbGeAlD
Olopatadine—HRH1—lung—hematologic cancer	0.000895	0.00928	CbGeAlD
Olopatadine—HRH1—testis—hematologic cancer	0.000845	0.00875	CbGeAlD
Olopatadine—CYP3A4—blood—hematologic cancer	0.00079	0.00818	CbGeAlD
Olopatadine—HRH1—lymph node—hematologic cancer	0.000612	0.00634	CbGeAlD
Olopatadine—S100A13—Ponatinib—Nilotinib—hematologic cancer	0.00053	0.0557	CbGdCrCtD
Olopatadine—Acepromazine—SLC22A1—hematologic cancer	0.000462	0.183	CrCbGaD
Olopatadine—S100A13—Adenosine monophosphate—Clofarabine—hematologic cancer	0.000447	0.0469	CbGdCrCtD
Olopatadine—Thiothixene—SLC22A1—hematologic cancer	0.000445	0.176	CrCbGaD
Olopatadine—S100A13—Adenosine monophosphate—Nelarabine—hematologic cancer	0.00042	0.0441	CbGdCrCtD
Olopatadine—S100A13—Vitamin A—Alitretinoin—hematologic cancer	0.000414	0.0435	CbGdCrCtD
Olopatadine—S100A13—Ponatinib—Imatinib—hematologic cancer	0.000402	0.0422	CbGdCrCtD
Olopatadine—Clomipramine—GSTP1—hematologic cancer	0.00038	0.151	CrCbGaD
Olopatadine—S100A13—Adenosine monophosphate—Fludarabine—hematologic cancer	0.000328	0.0344	CbGdCrCtD
Olopatadine—S100A13—Adenosine monophosphate—Cytarabine—hematologic cancer	0.00031	0.0325	CbGdCrCtD
Olopatadine—S100A13—Adenosine monophosphate—Cladribine—hematologic cancer	0.000302	0.0317	CbGdCrCtD
Olopatadine—Imipramine—SLC22A1—hematologic cancer	0.00024	0.0951	CrCbGaD
Olopatadine—Acepromazine—ALB—hematologic cancer	0.000141	0.0559	CrCbGaD
Olopatadine—Thiothixene—ALB—hematologic cancer	0.000135	0.0537	CrCbGaD
Olopatadine—Clomipramine—ALB—hematologic cancer	0.000107	0.0425	CrCbGaD
Olopatadine—Nortriptyline—ALB—hematologic cancer	0.000105	0.0415	CrCbGaD
Olopatadine—Clomipramine—ABCB1—hematologic cancer	0.000102	0.0405	CrCbGaD
Olopatadine—Chlorprothixene—ABCB1—hematologic cancer	0.000102	0.0404	CrCbGaD
Olopatadine—Doxepin—ABCB1—hematologic cancer	8.96e-05	0.0356	CrCbGaD
Olopatadine—Feeling abnormal—Prednisolone—hematologic cancer	7.61e-05	0.000233	CcSEcCtD
Olopatadine—Visual impairment—Methotrexate—hematologic cancer	7.61e-05	0.000233	CcSEcCtD
Olopatadine—Headache—Carmustine—hematologic cancer	7.59e-05	0.000232	CcSEcCtD
Olopatadine—Dyspnoea—Triamcinolone—hematologic cancer	7.57e-05	0.000232	CcSEcCtD
Olopatadine—Rash—Alitretinoin—hematologic cancer	7.57e-05	0.000232	CcSEcCtD
Olopatadine—Nervous system disorder—Dexamethasone—hematologic cancer	7.56e-05	0.000231	CcSEcCtD
Olopatadine—Nervous system disorder—Betamethasone—hematologic cancer	7.56e-05	0.000231	CcSEcCtD
Olopatadine—Dermatitis—Alitretinoin—hematologic cancer	7.56e-05	0.000231	CcSEcCtD
Olopatadine—Vomiting—Ifosfamide—hematologic cancer	7.54e-05	0.000231	CcSEcCtD
Olopatadine—Hypersensitivity—Cisplatin—hematologic cancer	7.53e-05	0.000231	CcSEcCtD
Olopatadine—Headache—Alitretinoin—hematologic cancer	7.52e-05	0.00023	CcSEcCtD
Olopatadine—Diarrhoea—Gemcitabine—hematologic cancer	7.51e-05	0.00023	CcSEcCtD
Olopatadine—Nausea—Thalidomide—hematologic cancer	7.49e-05	0.000229	CcSEcCtD
Olopatadine—Rash—Ifosfamide—hematologic cancer	7.48e-05	0.000229	CcSEcCtD
Olopatadine—Dermatitis—Ifosfamide—hematologic cancer	7.47e-05	0.000229	CcSEcCtD
Olopatadine—Dizziness—Irinotecan—hematologic cancer	7.45e-05	0.000228	CcSEcCtD
Olopatadine—Malaise—Prednisone—hematologic cancer	7.42e-05	0.000227	CcSEcCtD
Olopatadine—Rhinitis—Epirubicin—hematologic cancer	7.41e-05	0.000227	CcSEcCtD
Olopatadine—Body temperature increased—Etoposide—hematologic cancer	7.4e-05	0.000227	CcSEcCtD
Olopatadine—Abdominal pain—Etoposide—hematologic cancer	7.4e-05	0.000227	CcSEcCtD
Olopatadine—Urinary tract infection—Doxorubicin—hematologic cancer	7.4e-05	0.000227	CcSEcCtD
Olopatadine—Conjunctivitis—Doxorubicin—hematologic cancer	7.4e-05	0.000227	CcSEcCtD
Olopatadine—Eye disorder—Methotrexate—hematologic cancer	7.38e-05	0.000226	CcSEcCtD
Olopatadine—Hypoaesthesia—Epirubicin—hematologic cancer	7.35e-05	0.000225	CcSEcCtD
Olopatadine—Vomiting—Vincristine—hematologic cancer	7.35e-05	0.000225	CcSEcCtD
Olopatadine—Asthenia—Cisplatin—hematologic cancer	7.34e-05	0.000225	CcSEcCtD
Olopatadine—Pharyngitis—Epirubicin—hematologic cancer	7.34e-05	0.000225	CcSEcCtD
Olopatadine—Fatigue—Triamcinolone—hematologic cancer	7.32e-05	0.000224	CcSEcCtD
Olopatadine—Rash—Vincristine—hematologic cancer	7.29e-05	0.000223	CcSEcCtD
Olopatadine—Dermatitis—Vincristine—hematologic cancer	7.28e-05	0.000223	CcSEcCtD
Olopatadine—Pain—Triamcinolone—hematologic cancer	7.27e-05	0.000222	CcSEcCtD
Olopatadine—Amitriptyline—ALB—hematologic cancer	7.26e-05	0.0288	CrCbGaD
Olopatadine—Headache—Vincristine—hematologic cancer	7.24e-05	0.000222	CcSEcCtD
Olopatadine—Nausea—Carmustine—hematologic cancer	7.2e-05	0.00022	CcSEcCtD
Olopatadine—Epistaxis—Doxorubicin—hematologic cancer	7.18e-05	0.00022	CcSEcCtD
Olopatadine—Vomiting—Irinotecan—hematologic cancer	7.16e-05	0.000219	CcSEcCtD
Olopatadine—Vomiting—Mitoxantrone—hematologic cancer	7.16e-05	0.000219	CcSEcCtD
Olopatadine—Sinusitis—Doxorubicin—hematologic cancer	7.15e-05	0.000219	CcSEcCtD
Olopatadine—Immune system disorder—Methotrexate—hematologic cancer	7.13e-05	0.000218	CcSEcCtD
Olopatadine—Nausea—Alitretinoin—hematologic cancer	7.13e-05	0.000218	CcSEcCtD
Olopatadine—Visual impairment—Epirubicin—hematologic cancer	7.12e-05	0.000218	CcSEcCtD
Olopatadine—Mediastinal disorder—Methotrexate—hematologic cancer	7.12e-05	0.000218	CcSEcCtD
Olopatadine—Rash—Mitoxantrone—hematologic cancer	7.1e-05	0.000217	CcSEcCtD
Olopatadine—Rash—Irinotecan—hematologic cancer	7.1e-05	0.000217	CcSEcCtD
Olopatadine—Dermatitis—Irinotecan—hematologic cancer	7.09e-05	0.000217	CcSEcCtD
Olopatadine—Dermatitis—Mitoxantrone—hematologic cancer	7.09e-05	0.000217	CcSEcCtD
Olopatadine—Headache—Irinotecan—hematologic cancer	7.05e-05	0.000216	CcSEcCtD
Olopatadine—Headache—Mitoxantrone—hematologic cancer	7.05e-05	0.000216	CcSEcCtD
Olopatadine—Nausea—Ifosfamide—hematologic cancer	7.04e-05	0.000216	CcSEcCtD
Olopatadine—Feeling abnormal—Triamcinolone—hematologic cancer	7e-05	0.000214	CcSEcCtD
Olopatadine—Diarrhoea—Cisplatin—hematologic cancer	7e-05	0.000214	CcSEcCtD
Olopatadine—Vomiting—Gemcitabine—hematologic cancer	6.97e-05	0.000214	CcSEcCtD
Olopatadine—Imipramine—ABCB1—hematologic cancer	6.97e-05	0.0277	CrCbGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.95e-05	0.000213	CcSEcCtD
Olopatadine—Amitriptyline—ABCB1—hematologic cancer	6.93e-05	0.0275	CrCbGaD
Olopatadine—Discomfort—Prednisone—hematologic cancer	6.92e-05	0.000212	CcSEcCtD
Olopatadine—Rash—Gemcitabine—hematologic cancer	6.92e-05	0.000212	CcSEcCtD
Olopatadine—Dermatitis—Gemcitabine—hematologic cancer	6.91e-05	0.000212	CcSEcCtD
Olopatadine—Eye disorder—Epirubicin—hematologic cancer	6.91e-05	0.000211	CcSEcCtD
Olopatadine—Hypersensitivity—Etoposide—hematologic cancer	6.9e-05	0.000211	CcSEcCtD
Olopatadine—Erythema—Methotrexate—hematologic cancer	6.87e-05	0.00021	CcSEcCtD
Olopatadine—Headache—Gemcitabine—hematologic cancer	6.87e-05	0.00021	CcSEcCtD
Olopatadine—Nausea—Vincristine—hematologic cancer	6.87e-05	0.00021	CcSEcCtD
Olopatadine—Rhinitis—Doxorubicin—hematologic cancer	6.86e-05	0.00021	CcSEcCtD
Olopatadine—Hypersensitivity—Prednisolone—hematologic cancer	6.81e-05	0.000208	CcSEcCtD
Olopatadine—Hypoaesthesia—Doxorubicin—hematologic cancer	6.8e-05	0.000208	CcSEcCtD
Olopatadine—Pharyngitis—Doxorubicin—hematologic cancer	6.79e-05	0.000208	CcSEcCtD
Olopatadine—Dysgeusia—Methotrexate—hematologic cancer	6.73e-05	0.000206	CcSEcCtD
Olopatadine—Asthenia—Etoposide—hematologic cancer	6.72e-05	0.000206	CcSEcCtD
Olopatadine—Body temperature increased—Triamcinolone—hematologic cancer	6.72e-05	0.000206	CcSEcCtD
Olopatadine—Oedema—Prednisone—hematologic cancer	6.71e-05	0.000206	CcSEcCtD
Olopatadine—Nausea—Irinotecan—hematologic cancer	6.69e-05	0.000205	CcSEcCtD
Olopatadine—Nausea—Mitoxantrone—hematologic cancer	6.69e-05	0.000205	CcSEcCtD
Olopatadine—Immune system disorder—Epirubicin—hematologic cancer	6.68e-05	0.000204	CcSEcCtD
Olopatadine—Infection—Prednisone—hematologic cancer	6.67e-05	0.000204	CcSEcCtD
Olopatadine—Mediastinal disorder—Epirubicin—hematologic cancer	6.66e-05	0.000204	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.66e-05	0.000204	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.66e-05	0.000204	CcSEcCtD
Olopatadine—Back pain—Methotrexate—hematologic cancer	6.65e-05	0.000204	CcSEcCtD
Olopatadine—Fatigue—Dexamethasone—hematologic cancer	6.65e-05	0.000204	CcSEcCtD
Olopatadine—Fatigue—Betamethasone—hematologic cancer	6.65e-05	0.000204	CcSEcCtD
Olopatadine—Pruritus—Etoposide—hematologic cancer	6.63e-05	0.000203	CcSEcCtD
Olopatadine—Pain—Betamethasone—hematologic cancer	6.59e-05	0.000202	CcSEcCtD
Olopatadine—Pain—Dexamethasone—hematologic cancer	6.59e-05	0.000202	CcSEcCtD
Olopatadine—Visual impairment—Doxorubicin—hematologic cancer	6.59e-05	0.000202	CcSEcCtD
Olopatadine—Nervous system disorder—Prednisone—hematologic cancer	6.58e-05	0.000202	CcSEcCtD
Olopatadine—Skin disorder—Prednisone—hematologic cancer	6.52e-05	0.0002	CcSEcCtD
Olopatadine—Nausea—Gemcitabine—hematologic cancer	6.52e-05	0.0002	CcSEcCtD
Olopatadine—Vomiting—Cisplatin—hematologic cancer	6.5e-05	0.000199	CcSEcCtD
Olopatadine—Vision blurred—Methotrexate—hematologic cancer	6.48e-05	0.000198	CcSEcCtD
Olopatadine—Rash—Cisplatin—hematologic cancer	6.45e-05	0.000197	CcSEcCtD
Olopatadine—Dermatitis—Cisplatin—hematologic cancer	6.44e-05	0.000197	CcSEcCtD
Olopatadine—Erythema—Epirubicin—hematologic cancer	6.43e-05	0.000197	CcSEcCtD
Olopatadine—Diarrhoea—Etoposide—hematologic cancer	6.41e-05	0.000196	CcSEcCtD
Olopatadine—Eye disorder—Doxorubicin—hematologic cancer	6.39e-05	0.000196	CcSEcCtD
Olopatadine—Ill-defined disorder—Methotrexate—hematologic cancer	6.38e-05	0.000195	CcSEcCtD
Olopatadine—Feeling abnormal—Betamethasone—hematologic cancer	6.35e-05	0.000195	CcSEcCtD
Olopatadine—Feeling abnormal—Dexamethasone—hematologic cancer	6.35e-05	0.000195	CcSEcCtD
Olopatadine—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.3e-05	0.000193	CcSEcCtD
Olopatadine—Gastrointestinal pain—Betamethasone—hematologic cancer	6.3e-05	0.000193	CcSEcCtD
Olopatadine—Dysgeusia—Epirubicin—hematologic cancer	6.3e-05	0.000193	CcSEcCtD
Olopatadine—Hypersensitivity—Triamcinolone—hematologic cancer	6.26e-05	0.000192	CcSEcCtD
Olopatadine—Back pain—Epirubicin—hematologic cancer	6.22e-05	0.000191	CcSEcCtD
Olopatadine—Malaise—Methotrexate—hematologic cancer	6.2e-05	0.00019	CcSEcCtD
Olopatadine—Dizziness—Etoposide—hematologic cancer	6.19e-05	0.00019	CcSEcCtD
Olopatadine—Muscle spasms—Epirubicin—hematologic cancer	6.19e-05	0.000189	CcSEcCtD
Olopatadine—Immune system disorder—Doxorubicin—hematologic cancer	6.18e-05	0.000189	CcSEcCtD
Olopatadine—Mediastinal disorder—Doxorubicin—hematologic cancer	6.16e-05	0.000189	CcSEcCtD
Olopatadine—Dizziness—Prednisolone—hematologic cancer	6.11e-05	0.000187	CcSEcCtD
Olopatadine—Asthenia—Triamcinolone—hematologic cancer	6.1e-05	0.000187	CcSEcCtD
Olopatadine—Abdominal pain—Betamethasone—hematologic cancer	6.09e-05	0.000187	CcSEcCtD
Olopatadine—Body temperature increased—Betamethasone—hematologic cancer	6.09e-05	0.000187	CcSEcCtD
Olopatadine—Body temperature increased—Dexamethasone—hematologic cancer	6.09e-05	0.000187	CcSEcCtD
Olopatadine—Abdominal pain—Dexamethasone—hematologic cancer	6.09e-05	0.000187	CcSEcCtD
Olopatadine—Nausea—Cisplatin—hematologic cancer	6.07e-05	0.000186	CcSEcCtD
Olopatadine—Vision blurred—Epirubicin—hematologic cancer	6.06e-05	0.000186	CcSEcCtD
Olopatadine—Pruritus—Triamcinolone—hematologic cancer	6.01e-05	0.000184	CcSEcCtD
Olopatadine—Cough—Methotrexate—hematologic cancer	6e-05	0.000184	CcSEcCtD
Olopatadine—Ill-defined disorder—Epirubicin—hematologic cancer	5.97e-05	0.000183	CcSEcCtD
Olopatadine—Vomiting—Etoposide—hematologic cancer	5.96e-05	0.000182	CcSEcCtD
Olopatadine—Erythema—Doxorubicin—hematologic cancer	5.95e-05	0.000182	CcSEcCtD
Olopatadine—Rash—Etoposide—hematologic cancer	5.91e-05	0.000181	CcSEcCtD
Olopatadine—Dermatitis—Etoposide—hematologic cancer	5.9e-05	0.000181	CcSEcCtD
Olopatadine—Headache—Etoposide—hematologic cancer	5.87e-05	0.00018	CcSEcCtD
Olopatadine—Dysgeusia—Doxorubicin—hematologic cancer	5.83e-05	0.000178	CcSEcCtD
Olopatadine—Rash—Prednisolone—hematologic cancer	5.83e-05	0.000178	CcSEcCtD
Olopatadine—Dermatitis—Prednisolone—hematologic cancer	5.82e-05	0.000178	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.81e-05	0.000178	CcSEcCtD
Olopatadine—Malaise—Epirubicin—hematologic cancer	5.8e-05	0.000178	CcSEcCtD
Olopatadine—Fatigue—Prednisone—hematologic cancer	5.79e-05	0.000177	CcSEcCtD
Olopatadine—Headache—Prednisolone—hematologic cancer	5.79e-05	0.000177	CcSEcCtD
Olopatadine—Discomfort—Methotrexate—hematologic cancer	5.78e-05	0.000177	CcSEcCtD
Olopatadine—Back pain—Doxorubicin—hematologic cancer	5.76e-05	0.000176	CcSEcCtD
Olopatadine—Muscle spasms—Doxorubicin—hematologic cancer	5.72e-05	0.000175	CcSEcCtD
Olopatadine—Dizziness—Triamcinolone—hematologic cancer	5.62e-05	0.000172	CcSEcCtD
Olopatadine—Cough—Epirubicin—hematologic cancer	5.61e-05	0.000172	CcSEcCtD
Olopatadine—Vision blurred—Doxorubicin—hematologic cancer	5.61e-05	0.000172	CcSEcCtD
Olopatadine—Infection—Methotrexate—hematologic cancer	5.57e-05	0.000171	CcSEcCtD
Olopatadine—Nausea—Etoposide—hematologic cancer	5.56e-05	0.00017	CcSEcCtD
Olopatadine—Feeling abnormal—Prednisone—hematologic cancer	5.53e-05	0.000169	CcSEcCtD
Olopatadine—Asthenia—Betamethasone—hematologic cancer	5.53e-05	0.000169	CcSEcCtD
Olopatadine—Asthenia—Dexamethasone—hematologic cancer	5.53e-05	0.000169	CcSEcCtD
Olopatadine—Ill-defined disorder—Doxorubicin—hematologic cancer	5.52e-05	0.000169	CcSEcCtD
Olopatadine—Nervous system disorder—Methotrexate—hematologic cancer	5.5e-05	0.000168	CcSEcCtD
Olopatadine—Gastrointestinal pain—Prednisone—hematologic cancer	5.49e-05	0.000168	CcSEcCtD
Olopatadine—Nausea—Prednisolone—hematologic cancer	5.49e-05	0.000168	CcSEcCtD
Olopatadine—Pruritus—Betamethasone—hematologic cancer	5.45e-05	0.000167	CcSEcCtD
Olopatadine—Pruritus—Dexamethasone—hematologic cancer	5.45e-05	0.000167	CcSEcCtD
Olopatadine—Skin disorder—Methotrexate—hematologic cancer	5.45e-05	0.000167	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.44e-05	0.000167	CcSEcCtD
Olopatadine—Discomfort—Epirubicin—hematologic cancer	5.41e-05	0.000166	CcSEcCtD
Olopatadine—Vomiting—Triamcinolone—hematologic cancer	5.4e-05	0.000165	CcSEcCtD
Olopatadine—Malaise—Doxorubicin—hematologic cancer	5.37e-05	0.000164	CcSEcCtD
Olopatadine—Rash—Triamcinolone—hematologic cancer	5.36e-05	0.000164	CcSEcCtD
Olopatadine—Dry mouth—Epirubicin—hematologic cancer	5.36e-05	0.000164	CcSEcCtD
Olopatadine—Dermatitis—Triamcinolone—hematologic cancer	5.35e-05	0.000164	CcSEcCtD
Olopatadine—Headache—Triamcinolone—hematologic cancer	5.32e-05	0.000163	CcSEcCtD
Olopatadine—Body temperature increased—Prednisone—hematologic cancer	5.31e-05	0.000162	CcSEcCtD
Olopatadine—Abdominal pain—Prednisone—hematologic cancer	5.31e-05	0.000162	CcSEcCtD
Olopatadine—Diarrhoea—Betamethasone—hematologic cancer	5.27e-05	0.000161	CcSEcCtD
Olopatadine—Diarrhoea—Dexamethasone—hematologic cancer	5.27e-05	0.000161	CcSEcCtD
Olopatadine—Oedema—Epirubicin—hematologic cancer	5.25e-05	0.000161	CcSEcCtD
Olopatadine—Infection—Epirubicin—hematologic cancer	5.22e-05	0.00016	CcSEcCtD
Olopatadine—Cough—Doxorubicin—hematologic cancer	5.19e-05	0.000159	CcSEcCtD
Olopatadine—Nervous system disorder—Epirubicin—hematologic cancer	5.15e-05	0.000158	CcSEcCtD
Olopatadine—Skin disorder—Epirubicin—hematologic cancer	5.1e-05	0.000156	CcSEcCtD
Olopatadine—Dizziness—Betamethasone—hematologic cancer	5.1e-05	0.000156	CcSEcCtD
Olopatadine—Dizziness—Dexamethasone—hematologic cancer	5.1e-05	0.000156	CcSEcCtD
Olopatadine—Nausea—Triamcinolone—hematologic cancer	5.05e-05	0.000155	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.03e-05	0.000154	CcSEcCtD
Olopatadine—Discomfort—Doxorubicin—hematologic cancer	5.01e-05	0.000153	CcSEcCtD
Olopatadine—Dyspnoea—Methotrexate—hematologic cancer	5e-05	0.000153	CcSEcCtD
Olopatadine—Somnolence—Methotrexate—hematologic cancer	4.99e-05	0.000153	CcSEcCtD
Olopatadine—Dry mouth—Doxorubicin—hematologic cancer	4.96e-05	0.000152	CcSEcCtD
Olopatadine—Hypersensitivity—Prednisone—hematologic cancer	4.95e-05	0.000151	CcSEcCtD
Olopatadine—Vomiting—Dexamethasone—hematologic cancer	4.9e-05	0.00015	CcSEcCtD
Olopatadine—Vomiting—Betamethasone—hematologic cancer	4.9e-05	0.00015	CcSEcCtD
Olopatadine—Rash—Betamethasone—hematologic cancer	4.86e-05	0.000149	CcSEcCtD
Olopatadine—Rash—Dexamethasone—hematologic cancer	4.86e-05	0.000149	CcSEcCtD
Olopatadine—Oedema—Doxorubicin—hematologic cancer	4.86e-05	0.000149	CcSEcCtD
Olopatadine—Dermatitis—Betamethasone—hematologic cancer	4.86e-05	0.000149	CcSEcCtD
Olopatadine—Dermatitis—Dexamethasone—hematologic cancer	4.86e-05	0.000149	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.84e-05	0.000148	CcSEcCtD
Olopatadine—Fatigue—Methotrexate—hematologic cancer	4.84e-05	0.000148	CcSEcCtD
Olopatadine—Headache—Betamethasone—hematologic cancer	4.83e-05	0.000148	CcSEcCtD
Olopatadine—Headache—Dexamethasone—hematologic cancer	4.83e-05	0.000148	CcSEcCtD
Olopatadine—Infection—Doxorubicin—hematologic cancer	4.83e-05	0.000148	CcSEcCtD
Olopatadine—Asthenia—Prednisone—hematologic cancer	4.82e-05	0.000147	CcSEcCtD
Olopatadine—Pain—Methotrexate—hematologic cancer	4.8e-05	0.000147	CcSEcCtD
Olopatadine—Nervous system disorder—Doxorubicin—hematologic cancer	4.76e-05	0.000146	CcSEcCtD
Olopatadine—Pruritus—Prednisone—hematologic cancer	4.75e-05	0.000145	CcSEcCtD
Olopatadine—Skin disorder—Doxorubicin—hematologic cancer	4.72e-05	0.000144	CcSEcCtD
Olopatadine—Dyspnoea—Epirubicin—hematologic cancer	4.68e-05	0.000143	CcSEcCtD
Olopatadine—Somnolence—Epirubicin—hematologic cancer	4.67e-05	0.000143	CcSEcCtD
Olopatadine—Feeling abnormal—Methotrexate—hematologic cancer	4.62e-05	0.000142	CcSEcCtD
Olopatadine—Diarrhoea—Prednisone—hematologic cancer	4.59e-05	0.000141	CcSEcCtD
Olopatadine—Gastrointestinal pain—Methotrexate—hematologic cancer	4.59e-05	0.00014	CcSEcCtD
Olopatadine—Nausea—Betamethasone—hematologic cancer	4.58e-05	0.00014	CcSEcCtD
Olopatadine—Nausea—Dexamethasone—hematologic cancer	4.58e-05	0.00014	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.53e-05	0.000139	CcSEcCtD
Olopatadine—Fatigue—Epirubicin—hematologic cancer	4.53e-05	0.000139	CcSEcCtD
Olopatadine—Pain—Epirubicin—hematologic cancer	4.49e-05	0.000137	CcSEcCtD
Olopatadine—Dizziness—Prednisone—hematologic cancer	4.44e-05	0.000136	CcSEcCtD
Olopatadine—Body temperature increased—Methotrexate—hematologic cancer	4.44e-05	0.000136	CcSEcCtD
Olopatadine—Abdominal pain—Methotrexate—hematologic cancer	4.44e-05	0.000136	CcSEcCtD
Olopatadine—Dyspnoea—Doxorubicin—hematologic cancer	4.33e-05	0.000133	CcSEcCtD
Olopatadine—Feeling abnormal—Epirubicin—hematologic cancer	4.33e-05	0.000132	CcSEcCtD
Olopatadine—Somnolence—Doxorubicin—hematologic cancer	4.32e-05	0.000132	CcSEcCtD
Olopatadine—Gastrointestinal pain—Epirubicin—hematologic cancer	4.29e-05	0.000131	CcSEcCtD
Olopatadine—Vomiting—Prednisone—hematologic cancer	4.27e-05	0.000131	CcSEcCtD
Olopatadine—Rash—Prednisone—hematologic cancer	4.23e-05	0.00013	CcSEcCtD
Olopatadine—Dermatitis—Prednisone—hematologic cancer	4.23e-05	0.000129	CcSEcCtD
Olopatadine—Headache—Prednisone—hematologic cancer	4.21e-05	0.000129	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.19e-05	0.000128	CcSEcCtD
Olopatadine—Fatigue—Doxorubicin—hematologic cancer	4.19e-05	0.000128	CcSEcCtD
Olopatadine—Pain—Doxorubicin—hematologic cancer	4.15e-05	0.000127	CcSEcCtD
Olopatadine—Body temperature increased—Epirubicin—hematologic cancer	4.15e-05	0.000127	CcSEcCtD
Olopatadine—Abdominal pain—Epirubicin—hematologic cancer	4.15e-05	0.000127	CcSEcCtD
Olopatadine—Hypersensitivity—Methotrexate—hematologic cancer	4.13e-05	0.000127	CcSEcCtD
Olopatadine—Asthenia—Methotrexate—hematologic cancer	4.03e-05	0.000123	CcSEcCtD
Olopatadine—Feeling abnormal—Doxorubicin—hematologic cancer	4e-05	0.000123	CcSEcCtD
Olopatadine—Nausea—Prednisone—hematologic cancer	3.99e-05	0.000122	CcSEcCtD
Olopatadine—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.97e-05	0.000122	CcSEcCtD
Olopatadine—Pruritus—Methotrexate—hematologic cancer	3.97e-05	0.000122	CcSEcCtD
Olopatadine—Hypersensitivity—Epirubicin—hematologic cancer	3.87e-05	0.000118	CcSEcCtD
Olopatadine—Body temperature increased—Doxorubicin—hematologic cancer	3.84e-05	0.000118	CcSEcCtD
Olopatadine—Abdominal pain—Doxorubicin—hematologic cancer	3.84e-05	0.000118	CcSEcCtD
Olopatadine—Diarrhoea—Methotrexate—hematologic cancer	3.84e-05	0.000118	CcSEcCtD
Olopatadine—Asthenia—Epirubicin—hematologic cancer	3.77e-05	0.000115	CcSEcCtD
Olopatadine—Pruritus—Epirubicin—hematologic cancer	3.71e-05	0.000114	CcSEcCtD
Olopatadine—Dizziness—Methotrexate—hematologic cancer	3.71e-05	0.000114	CcSEcCtD
Olopatadine—Diarrhoea—Epirubicin—hematologic cancer	3.59e-05	0.00011	CcSEcCtD
Olopatadine—Hypersensitivity—Doxorubicin—hematologic cancer	3.58e-05	0.00011	CcSEcCtD
Olopatadine—Vomiting—Methotrexate—hematologic cancer	3.57e-05	0.000109	CcSEcCtD
Olopatadine—Rash—Methotrexate—hematologic cancer	3.54e-05	0.000108	CcSEcCtD
Olopatadine—Dermatitis—Methotrexate—hematologic cancer	3.53e-05	0.000108	CcSEcCtD
Olopatadine—Headache—Methotrexate—hematologic cancer	3.51e-05	0.000108	CcSEcCtD
Olopatadine—Asthenia—Doxorubicin—hematologic cancer	3.49e-05	0.000107	CcSEcCtD
Olopatadine—Dizziness—Epirubicin—hematologic cancer	3.47e-05	0.000106	CcSEcCtD
Olopatadine—Pruritus—Doxorubicin—hematologic cancer	3.44e-05	0.000105	CcSEcCtD
Olopatadine—Vomiting—Epirubicin—hematologic cancer	3.34e-05	0.000102	CcSEcCtD
Olopatadine—Nausea—Methotrexate—hematologic cancer	3.33e-05	0.000102	CcSEcCtD
Olopatadine—Diarrhoea—Doxorubicin—hematologic cancer	3.32e-05	0.000102	CcSEcCtD
Olopatadine—Rash—Epirubicin—hematologic cancer	3.31e-05	0.000101	CcSEcCtD
Olopatadine—Dermatitis—Epirubicin—hematologic cancer	3.31e-05	0.000101	CcSEcCtD
Olopatadine—Headache—Epirubicin—hematologic cancer	3.29e-05	0.000101	CcSEcCtD
Olopatadine—Dizziness—Doxorubicin—hematologic cancer	3.21e-05	9.84e-05	CcSEcCtD
Olopatadine—Nausea—Epirubicin—hematologic cancer	3.12e-05	9.55e-05	CcSEcCtD
Olopatadine—Vomiting—Doxorubicin—hematologic cancer	3.09e-05	9.46e-05	CcSEcCtD
Olopatadine—Rash—Doxorubicin—hematologic cancer	3.06e-05	9.38e-05	CcSEcCtD
Olopatadine—Dermatitis—Doxorubicin—hematologic cancer	3.06e-05	9.37e-05	CcSEcCtD
Olopatadine—Headache—Doxorubicin—hematologic cancer	3.04e-05	9.32e-05	CcSEcCtD
Olopatadine—Nausea—Doxorubicin—hematologic cancer	2.89e-05	8.84e-05	CcSEcCtD
Olopatadine—CYP3A4—Metabolism—PHYH—hematologic cancer	1.61e-05	7.48e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GMPS—hematologic cancer	1.61e-05	7.48e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—FTCD—hematologic cancer	1.61e-05	7.48e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FGF2—hematologic cancer	1.59e-05	7.39e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCR4—hematologic cancer	1.59e-05	7.38e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—KRAS—hematologic cancer	1.57e-05	7.3e-05	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	1.57e-05	7.3e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3R1—hematologic cancer	1.57e-05	7.29e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL13—hematologic cancer	1.55e-05	7.2e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCR7—hematologic cancer	1.55e-05	7.2e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL3—hematologic cancer	1.53e-05	7.12e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NCOR2—hematologic cancer	1.53e-05	7.1e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—JAK2—hematologic cancer	1.53e-05	7.09e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL3RA—hematologic cancer	1.51e-05	7.01e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CRKL—hematologic cancer	1.51e-05	7.01e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MDM2—hematologic cancer	1.49e-05	6.92e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—KRAS—hematologic cancer	1.49e-05	6.91e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—RASGRP1—hematologic cancer	1.48e-05	6.88e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.47e-05	6.84e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—GRB2—hematologic cancer	1.47e-05	6.82e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RGS2—hematologic cancer	1.46e-05	6.76e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MTOR—hematologic cancer	1.45e-05	6.73e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CB—hematologic cancer	1.45e-05	6.73e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PIK3CA—hematologic cancer	1.44e-05	6.71e-05	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	1.44e-05	6.7e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TRIO—hematologic cancer	1.44e-05	6.69e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TRH—hematologic cancer	1.44e-05	6.69e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CMA1—hematologic cancer	1.44e-05	6.69e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AGO2—hematologic cancer	1.41e-05	6.55e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SPHK1—hematologic cancer	1.41e-05	6.55e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HDAC9—hematologic cancer	1.39e-05	6.48e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LPAR1—hematologic cancer	1.39e-05	6.48e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—H3F3B—hematologic cancer	1.38e-05	6.41e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—PIK3CA—hematologic cancer	1.37e-05	6.35e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1B—hematologic cancer	1.36e-05	6.32e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HRAS—hematologic cancer	1.34e-05	6.21e-05	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	1.33e-05	6.2e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CASP3—hematologic cancer	1.33e-05	6.19e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—GRB2—hematologic cancer	1.33e-05	6.19e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL2—hematologic cancer	1.33e-05	6.18e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CSF2—hematologic cancer	1.31e-05	6.09e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCND1—hematologic cancer	1.3e-05	6.03e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—JUN—hematologic cancer	1.29e-05	6.01e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ASNS—hematologic cancer	1.29e-05	5.98e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—DCK—hematologic cancer	1.29e-05	5.98e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.29e-05	5.98e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDE4B—hematologic cancer	1.28e-05	5.96e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CNR2—hematologic cancer	1.28e-05	5.96e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6—hematologic cancer	1.28e-05	5.94e-05	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	1.28e-05	5.94e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGF19—hematologic cancer	1.27e-05	5.91e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PRKCG—hematologic cancer	1.26e-05	5.88e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—JAK1—hematologic cancer	1.26e-05	5.88e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—HRAS—hematologic cancer	1.26e-05	5.87e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RAC2—hematologic cancer	1.26e-05	5.87e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1A—hematologic cancer	1.25e-05	5.83e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—DKK1—hematologic cancer	1.25e-05	5.82e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTEN—hematologic cancer	1.25e-05	5.82e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT5B—hematologic cancer	1.24e-05	5.77e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MAPK8—hematologic cancer	1.22e-05	5.69e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HDC—hematologic cancer	1.22e-05	5.67e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6—hematologic cancer	1.21e-05	5.62e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ADCY7—hematologic cancer	1.21e-05	5.61e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EP300—hematologic cancer	1.19e-05	5.55e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CSF2—hematologic cancer	1.19e-05	5.53e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—IL2RA—hematologic cancer	1.18e-05	5.49e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AKT1—hematologic cancer	1.18e-05	5.48e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—XIAP—hematologic cancer	1.17e-05	5.45e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SRC—hematologic cancer	1.16e-05	5.39e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PRKCG—hematologic cancer	1.15e-05	5.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—JAK1—hematologic cancer	1.15e-05	5.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SMARCA4—hematologic cancer	1.14e-05	5.31e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SH2B3—hematologic cancer	1.14e-05	5.31e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GZMB—hematologic cancer	1.14e-05	5.28e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—VEGFA—hematologic cancer	1.13e-05	5.25e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—STAT3—hematologic cancer	1.12e-05	5.2e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NRAS—hematologic cancer	1.12e-05	5.19e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CDA—hematologic cancer	1.12e-05	5.19e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—AKT1—hematologic cancer	1.12e-05	5.18e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CTNNA1—hematologic cancer	1.11e-05	5.16e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HSPB1—hematologic cancer	1.1e-05	5.13e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EIF4EBP1—hematologic cancer	1.1e-05	5.13e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL3—hematologic cancer	1.1e-05	5.13e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTHLH—hematologic cancer	1.09e-05	5.07e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SDC1—hematologic cancer	1.09e-05	5.07e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PC—hematologic cancer	1.07e-05	4.99e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL2RA—hematologic cancer	1.07e-05	4.98e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MAPK3—hematologic cancer	1.07e-05	4.97e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTGER4—hematologic cancer	1.06e-05	4.94e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LCK—hematologic cancer	1.06e-05	4.91e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MYC—hematologic cancer	1.04e-05	4.83e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GBA—hematologic cancer	1.04e-05	4.82e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.04e-05	4.82e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TGFB1—hematologic cancer	1.04e-05	4.82e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—H3F3A—hematologic cancer	1.04e-05	4.81e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PRKCZ—hematologic cancer	1.01e-05	4.68e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CG—hematologic cancer	9.84e-06	4.57e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PARP1—hematologic cancer	9.72e-06	4.52e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KRAS—hematologic cancer	9.61e-06	4.47e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FBXW7—hematologic cancer	9.57e-06	4.45e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTAP—hematologic cancer	9.49e-06	4.41e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HDAC2—hematologic cancer	9.38e-06	4.36e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCR4—hematologic cancer	9.38e-06	4.36e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CBL—hematologic cancer	9.14e-06	4.25e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL3—hematologic cancer	9.05e-06	4.2e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CG—hematologic cancer	8.94e-06	4.15e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTPN1—hematologic cancer	8.89e-06	4.13e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CA—hematologic cancer	8.83e-06	4.1e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PTPN11—hematologic cancer	8.78e-06	4.08e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RASGRP1—hematologic cancer	8.75e-06	4.07e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HSP90AA1—hematologic cancer	8.72e-06	4.05e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SYK—hematologic cancer	8.72e-06	4.05e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CD—hematologic cancer	8.65e-06	4.02e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—hematologic cancer	8.54e-06	3.97e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CREB1—hematologic cancer	8.51e-06	3.95e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—FHL2—hematologic cancer	8.46e-06	3.93e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT1—hematologic cancer	8.41e-06	3.91e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL2—hematologic cancer	8.32e-06	3.87e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6R—hematologic cancer	8.3e-06	3.86e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AGRN—hematologic cancer	8.3e-06	3.86e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3R1—hematologic cancer	8.17e-06	3.8e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HRAS—hematologic cancer	8.17e-06	3.8e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—JAK2—hematologic cancer	7.94e-06	3.69e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MAP2K1—hematologic cancer	7.91e-06	3.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GRB2—hematologic cancer	7.87e-06	3.66e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—IDH2—hematologic cancer	7.86e-06	3.65e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HMMR—hematologic cancer	7.86e-06	3.65e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CD—hematologic cancer	7.86e-06	3.65e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDGFA—hematologic cancer	7.85e-06	3.65e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6—hematologic cancer	7.82e-06	3.63e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KITLG—hematologic cancer	7.74e-06	3.6e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT5A—hematologic cancer	7.56e-06	3.51e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CB—hematologic cancer	7.54e-06	3.5e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN2B—hematologic cancer	7.5e-06	3.48e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3R1—hematologic cancer	7.42e-06	3.45e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ARNTL—hematologic cancer	7.39e-06	3.44e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CD86—hematologic cancer	7.25e-06	3.37e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKT1—hematologic cancer	7.21e-06	3.35e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—JAK2—hematologic cancer	7.21e-06	3.35e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CA9—hematologic cancer	7.19e-06	3.34e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ACP5—hematologic cancer	7.19e-06	3.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HES1—hematologic cancer	7.15e-06	3.32e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NCOR1—hematologic cancer	7.11e-06	3.3e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NCOR2—hematologic cancer	7.1e-06	3.3e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGF1—hematologic cancer	7.03e-06	3.27e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CSF2—hematologic cancer	7.03e-06	3.27e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FOXO1—hematologic cancer	6.93e-06	3.22e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—IL2—hematologic cancer	6.92e-06	3.22e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDGFRB—hematologic cancer	6.92e-06	3.21e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CB—hematologic cancer	6.85e-06	3.18e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDGFRA—hematologic cancer	6.81e-06	3.16e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—JAK1—hematologic cancer	6.79e-06	3.15e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PRKCG—hematologic cancer	6.79e-06	3.15e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—IDH1—hematologic cancer	6.76e-06	3.14e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.69e-06	3.11e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TXN—hematologic cancer	6.69e-06	3.11e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.69e-06	3.11e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.54e-06	3.04e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL2RA—hematologic cancer	6.34e-06	2.94e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL2—hematologic cancer	6.29e-06	2.92e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	6.29e-06	2.92e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TERT—hematologic cancer	6.27e-06	2.91e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	6.12e-06	2.84e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CRABP1—hematologic cancer	6.12e-06	2.84e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDGFB—hematologic cancer	6.12e-06	2.84e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TSC2—hematologic cancer	5.98e-06	2.78e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.96e-06	2.77e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NUP98—hematologic cancer	5.77e-06	2.68e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGFR3—hematologic cancer	5.75e-06	2.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAPK14—hematologic cancer	5.69e-06	2.65e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.6e-06	2.6e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.6e-06	2.6e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ESR1—hematologic cancer	5.58e-06	2.6e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NUP214—hematologic cancer	5.56e-06	2.59e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FN1—hematologic cancer	5.52e-06	2.56e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTR—hematologic cancer	5.45e-06	2.53e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.45e-06	2.53e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NFKBIA—hematologic cancer	5.45e-06	2.53e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—BAD—hematologic cancer	5.45e-06	2.53e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOTCH1—hematologic cancer	5.4e-06	2.51e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ENO2—hematologic cancer	5.35e-06	2.48e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CD80—hematologic cancer	5.29e-06	2.46e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CG—hematologic cancer	5.28e-06	2.45e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KIT—hematologic cancer	5.28e-06	2.45e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—NRAS—hematologic cancer	5.28e-06	2.45e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTPN11—hematologic cancer	5.19e-06	2.41e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.18e-06	2.41e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SDC1—hematologic cancer	5.07e-06	2.35e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MAPK3—hematologic cancer	5.06e-06	2.35e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CREB1—hematologic cancer	5.02e-06	2.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—BRAF—hematologic cancer	4.96e-06	2.31e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL2—hematologic cancer	4.92e-06	2.28e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6R—hematologic cancer	4.9e-06	2.28e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CREBBP—hematologic cancer	4.89e-06	2.27e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAP2K1—hematologic cancer	4.67e-06	2.17e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CD—hematologic cancer	4.64e-06	2.16e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.6e-06	2.14e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KRAS—hematologic cancer	4.54e-06	2.11e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGF2—hematologic cancer	4.44e-06	2.06e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3R1—hematologic cancer	4.38e-06	2.04e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CD44—hematologic cancer	4.31e-06	2e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NQO1—hematologic cancer	4.31e-06	2e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—JAK2—hematologic cancer	4.26e-06	1.98e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CA—hematologic cancer	4.17e-06	1.94e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MDM2—hematologic cancer	4.16e-06	1.93e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYCS—hematologic cancer	4.08e-06	1.89e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4.05e-06	1.88e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MTOR—hematologic cancer	4.05e-06	1.88e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	4.05e-06	1.88e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—HRAS—hematologic cancer	3.86e-06	1.79e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	3.8e-06	1.76e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	3.76e-06	1.74e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CASP3—hematologic cancer	3.72e-06	1.73e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL2—hematologic cancer	3.71e-06	1.73e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6—hematologic cancer	3.7e-06	1.72e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCND1—hematologic cancer	3.62e-06	1.68e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—JUN—hematologic cancer	3.61e-06	1.68e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.59e-06	1.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	3.5e-06	1.63e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTEN—hematologic cancer	3.5e-06	1.62e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAPK8—hematologic cancer	3.42e-06	1.59e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKT1—hematologic cancer	3.41e-06	1.58e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.4e-06	1.58e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EP300—hematologic cancer	3.33e-06	1.55e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.3e-06	1.53e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.3e-06	1.53e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SRC—hematologic cancer	3.24e-06	1.51e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VEGFA—hematologic cancer	3.16e-06	1.47e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT3—hematologic cancer	3.13e-06	1.45e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NRAS—hematologic cancer	3.12e-06	1.45e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAPK3—hematologic cancer	2.99e-06	1.39e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.92e-06	1.36e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MYC—hematologic cancer	2.9e-06	1.35e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFB1—hematologic cancer	2.9e-06	1.35e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KRAS—hematologic cancer	2.68e-06	1.25e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	2.47e-06	1.15e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.45e-06	1.14e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—hematologic cancer	2.39e-06	1.11e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HRAS—hematologic cancer	2.28e-06	1.06e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.27e-06	1.06e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6—hematologic cancer	2.18e-06	1.01e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.16e-06	1e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ALB—hematologic cancer	2.13e-06	9.89e-06	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.04e-06	9.46e-06	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKT1—hematologic cancer	2.01e-06	9.36e-06	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.88e-06	8.73e-06	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTEN—hematologic cancer	1.62e-06	7.55e-06	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—EP300—hematologic cancer	1.55e-06	7.2e-06	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.15e-06	5.32e-06	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKT1—hematologic cancer	9.36e-07	4.35e-06	CbGpPWpGaD
